The Role of “Good Cholesterol” in AMD
Principal Investigator
Chi Luu, PhD
Centre for Eye Research Australia (Australia)
East Melbourne, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$160,000
Active Dates
July 18, 2018 - March 31, 2021
Grant ID
M2018144
Co-Principal Investigator(s)
Gregory Dusting, PhD, Centre for Eye Research Australia (Australia)
Robyn Guymer, MBBS, PhD, Centre for Eye Research Australia (Australia)
Goals
The protective properties of high-density lipoprotein (HDL), “good cholesterol”, have been studied extensively in cardiovascular conditions. Chronic inflammation modifies HDL (to dysfunctional HDL) and impairs its positive functional properties such as antioxidant and anti-inflammatory actions. Restoring HDL function has been shown to inhibit inflammation and oxidative stress, and in turn, reduces the risk of cardiovascular diseases in humans. Given that age-related macular degeneration (AMD), an eye condition that causes the loss of central vision, and cardiovascular disease share many common risk factors, we hypothesized that HDL functionality has a role in the development and progression of AMD. The overall aim of this research project is to explore the role and therapeutic benefit of HDL in AMD.
Summary
The role of HDL in the development and progression of AMD is unknown. This study will address this important knowledge gap and will potentially change our understanding of the role of HDL on the pathogenesis of AMD. To examine the role of HDL in AMD, we will collect blood from AMD and age-matched healthy subjects. Using the blood collected we will assess various HDL properties including anti-oxidant and anti-inflammatory capacity. We anticipate that the HDL function is compromised in subjects with AMD.
We will also investigate whether AMD can be treated with a reconstituted form of good cholesterol. We will address this question by determining whether reconstituted HDL will improve the structure and function of the retina in a preclinical model of AMD.
The findings from this project will pave the way for the development of new therapies for the management of the earliest changes in AMD to prevent vision loss. There are no treatment options currently available for the early stages of AMD to prevent its progression to vision loss.
Grants
Related Grants
Macular Degeneration Research
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Macular Degeneration Research
Understanding Early Molecular Events in Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Sandeep Moothedath Subrahmanian, PhD
Understanding Early Molecular Events in Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Sandeep Moothedath Subrahmanian, PhD
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD